Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Yoshimasa Shiraishi"'
Autor:
Yoshihiro Yamamoto, Daisuke Shibahara, Taro Mori, Kohei Otsubo, Yoshimasa Shiraishi, Yasuto Yoneshima, Eiji Iwama, Kentaro Tanaka, Yoshinao Oda, Isamu Okamoto
Publikováno v:
Thoracic Cancer, Vol 15, Iss 13, Pp 1106-1111 (2024)
Abstract Tracheomediastinal fistula is a rare but life‐threatening complication of cancer. We report a case of tracheomediastinal fistula induced by concurrent chemoradiotherapy in limited stage small cell lung cancer. Despite the treatment respons
Externí odkaz:
https://doaj.org/article/3dd6dd6ee9bd48c088fd5ca776e5f172
Autor:
Kousei Nakatsuru, Kazuya Tsubouchi, Minori Hirahata, Tadayuki Nakashima, Yuriko Takahata, Yuki Okamatsu, Yoshimasa Shiraishi, Isamu Okamoto, Taishi Harada
Publikováno v:
Thoracic Cancer, Vol 14, Iss 22, Pp 2225-2228 (2023)
Abstract Therapy related‐acute myeloid leukemia (t‐AML) and myelodysplastic syndrome (t‐MDS) are complications of chemotherapy and/or radiation therapy for malignant diseases. In this report, we describe a patient with advanced lung adenocarcin
Externí odkaz:
https://doaj.org/article/3c543c2885a14208b645a0d476187b1c
Autor:
Yuka Oku, Gouji Toyokawa, Sho Wakasu, Fumihiko Kinoshita, Shinkichi Takamori, Kenji Watanabe, Naoki Haratake, Taichi Nagano, Keisuke Kosai, Kazuki Takada, Airi Fujimoto, Kodo Higashijima, Yoshimasa Shiraishi, Kentaro Tanaka, Hiroaki Takeoka, Masaki Okamoto, Takanori Yamashita, Mototsugu Shimokawa, Fumihiro Shoji, Koji Yamazaki, Tatsuro Okamoto, Takashi Seto, Hitoshi Ueda, Sadanori Takeo, Naoki Nakashima, Isamu Okamoto, Tomoyoshi Takenaka, Tomoharu Yoshizumi
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 14327-14336 (2023)
Abstract Background Immunotherapy has become a standard‐of‐care for patients with non‐small‐cell lung cancer (NSCLC). Although several biomarkers, such as programmed cell death‐1, have been shown to be useful in selecting patients likely to
Externí odkaz:
https://doaj.org/article/dd568051ef63481493a1e9c73bb90058
Autor:
Daisuke Hazama, MD, PhD, Kenji Nakahama, MD, PhD, Hiroaki Kodama, MD, Akito Miyazaki, MD, Koichi Azuma, MD, PhD, Yosuke Kawashima, MD, Yuki Sato, MD, Kentaro Ito, MD, Yoshimasa Shiraishi, MD, Keita Miura, MD, Takayuki Takahama, MD, PhD, Satoshi Oizumi, MD, PhD, Yoshinobu Namba, MD, Satoshi Ikeda, MD, PhD, Hiroshige Yoshioka, MD, PhD, Asuka Tsuya, MD, PhD, Yuichiro Yasuda, MD, PhD, Yoshiki Negi, MD, PhD, Ayako Hara, MD, Michihito Toda, MD, PhD, Motoko Tachihara, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 1, Pp 100613- (2024)
Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of lung cancer associated with poor prognosis and resistance to conventional chemotherapy. Immune checkpoint inhibitors (ICIs), alone or in combination with chemotherapy, were foun
Externí odkaz:
https://doaj.org/article/ceb8623f26cd4608b0d8ffd019ba6537
Autor:
Koichi Goto, Yoshimasa Shiraishi, Haruyasu Murakami, Hidehito Horinouchi, Ryo Toyozawa, Masayuki Takeda, Makiko Uno, Nigel Crawford, Joseph McGill, Takeshi Jimbo, Masato Ishigami, Gensuke Takayama, Shintaro Nakayama, Shoichi Ohwada, Makoto Nishio
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 7090-7104 (2023)
Abstract Background Tyrosine kinase inhibitors (TKIs) are effective for the treatment of non‐small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth factor receptor (EGFR), but responses are not durable as tumors d
Externí odkaz:
https://doaj.org/article/4ccb84ac3b1f40d88e709e0bae4a3f6b
Autor:
Daichi Fujimoto, Satoru Miura, Keisuke Tomii, Hiromitsu Sumikawa, Kenichi Yoshimura, Kazushige Wakuda, Yuko Oya, Toshihide Yokoyama, Takashi Kijima, Tetsuhiko Asao, Motohiro Tamiya, Atsushi Nakamura, Hiroshige Yoshioka, Takaaki Tokito, Shuji Murakami, Akihiro Tamiya, Hiroshi Yokouchi, Satoshi Watanabe, Ou Yamaguchi, Ryotaro Morinaga, Takayuki Jodai, Kentaro Ito, Yoshimasa Shiraishi, Yoshihito Kogure, Ryota Shibaki, Nobuyuki Yamamoto
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Studies elucidating detailed characteristics of pneumonitis in association with chemo-immunotherapy are limited. We aimed to investigate the characteristics of images, prognostic factors, and clinical course of combination therapy associated
Externí odkaz:
https://doaj.org/article/d7954e13f28249d198db8ce843bb07a9
Autor:
Yoshimasa Shiraishi, Junji Kishimoto, Takayuki Shimose, Yukihiro Toi, Shunichi Sugawara, Isamu Okamoto
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-5 (2022)
Abstract Background First-line treatment of nonsquamous non–small cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination therapy together with immune checkpoint inhibitors (ICIs). However, phase III studies of combinations
Externí odkaz:
https://doaj.org/article/fad4a98eec924a8eac91b100e7450863
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 10, Iss , Pp 100236- (2023)
Externí odkaz:
https://doaj.org/article/ce350e3dccc64b48a2a5c99f6987a694
Autor:
Tadayuki Nakashima, Yoshimasa Shiraishi, Ayaka Shiota, Yasuto Yoneshima, Eiji Iwama, Kentaro Tanaka, Isamu Okamoto
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 10, Iss , Pp 100231- (2023)
We report a case of bronchiolitis obliterans (BO) due to afatinib treatment. A 42-year-old woman was diagnosed with stage IVB lung adenocarcinoma (cT1bN3M1c) positive for the L861Q mutation of EGFR and was treated with afatinib. Seven months after th
Externí odkaz:
https://doaj.org/article/1dd11d90d18048ffbd4c1c6347149b82
Autor:
Yuri Taniguchi, Tsuneo Shimokawa, Yuichi Takiguchi, Toshihiro Misumi, Yukiko Nakamura, Yosuke Kawashima, Naoki Furuya, Yoshimasa Shiraishi, Toshiyuki Harada, Hisashi Tanaka, Satoru Miura, Ayumi Uchiyama, Yoshiro Nakahara, Takaaki Tokito, Katsuhiko Naoki, Akihiro Bessho, Yasuhiro Goto, Masahiro Seike, Hiroaki Okamoto
Publikováno v:
Clinical Cancer Research. 28:4402-4409
Purpose: The addition of cytotoxic chemotherapy to immune-checkpoint inhibitor (ICI) may enhance antitumor effects. We conducted an open-label randomized phase II/III study to evaluate nivolumab + docetaxel combination therapy in comparison with nivo